Boston Heart Lab, a Framingham, MA-based developer of specialized diagnostics for patients with heart disease, has completed a $10m Series C round of financing.
The round was led by Bain Capital Ventures.
In conjunction with the funding, Alice Limkakeng and Jeff Crisan, both from Bain, join the company’s board of directors.
Boston Heart Lab has also named Susan Hertzberg as new CEO. She brings over 20 years of experience in global diagnostics companies.
Ms. Hertzberg is the former president and CEO of Ipsogen, Inc., the North American division of French cancer and molecular-diagnostics company, Ipsogen, SA. Ms. Hertzberg, who will also serve on the company’s board of directors, succeeds BHL’s founding CEO, Wolfgang Daum, Ph.D., who will remain a consultant to BHL.
Boston Heart Lab currently offers over 35 proprietary tests to assess the patient’s cardiac health and risk profile, thus enabling cardiologists and other clinicians to prescribe personalized treatment plans.